Reports Q2 revenue $2.4B, consensus $2.39B. “We delivered another strong quarter, with base business revenue growth of nearly 4% and total revenue growth of 2.5% as well as continued improvement in productivity and profitability in the base business,” said Jim Davis, Chairman, CEO and President. “This performance is due to growth of new physician and hospital customers, more favorable test mix that includes greater adoption of advanced diagnostics and continued strength in healthcare utilization. We also made progress improving our operational quality and efficiency through greater use of automation and AI.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- DGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Haystack Oncology, Lisata Therapeutics initiate research collaboration
- Quest Diagnostics price target raised to $158 from $150 at Truist
- Quest Diagnostics to acquire certain assets from OhioHealth